Ultragenyx to Present at the 42nd Annual J.P. Morgan Healthcare Conference
NOVATO, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) — Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for serious rare and ultrarare genetic diseases, today announced that Emil D. Kakkis, M.D., Ph.D., the company’s chief executive officer and president, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024, at 3:00 PM PT.
Related news for (RARE)
- Ultragenyx Announces Data Demonstrating Treatment with UX111 Results in Significant Reduction in Heparan Sulfate Exposure in Cerebrospinal Fluid Correlated with Improved Long-term Cognitive Function in Patients with Sanfilippo Syndrome Type A (MPS IIIA)
- Ultragenyx Receives PRIME Designation from European Medicines Agency (EMA) for GTX-102 for the Treatment of Angelman Syndrome
- Ultragenyx anuncia la aprobación de Dojolvi® (triheptanoína) para su inclusión en el Compendio Nacional de Insumos para la Salud de México en el tratamiento de los trastornos de oxidación de ácidos grasos de cadena larga (LC-FAOD)
- Ultragenyx Announces Completion of Dosing Across Stage 1 Cohorts in Pivotal Phase 1/2/3 Cyprus2+ Study Evaluating UX701 Gene Therapy for the Treatment of Wilson Disease
- Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)